Quantitative Diagnostics of Parkinsonian Syndromes Using Multi-modal Neuroimaging and Deep Learning
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Imaging biomarker that discriminates different neurodegenerative diseases
研究概览
简要总结
The goals of this study are: 1) to identify biomarkers using neuroimaging that are associated with progression rate using statistical methods, and 2) to identify biomarkers that are associated with the differential diagnosis of Parkinson's disease and atypical parkinsonism.
详细描述
Management of patients with parkinsonian symptoms has two critical gaps: (1) there are no clinically accepted biomarkers that may be used to inform disease progression rate in an individual with Parkinson disease (PD), and (2) no biomarkers exist to inform differential diagnosis of conditions that exhibit parkinsonian symptoms and signs. This 2-year study aims to develop a multi-modal neuroimaging biomarker that enables the prediction of disease progression rate in PD, and a biomarker that enables the differential diagnosis of PD, multiple systems atrophy (MSA), progressive supranuclear palsy (PSP), and healthy controls.
This study consists of two parts; neuroimaging of a defined population of mid to late stage PD subjects currently followed at UT Southwestern Medical Center, and recruitment of new subjects with PD, MSA, and PSP who will be followed clinically over 2 years and who will undergo neuroimaging.
Participants will be asked to undergo several types of neuroimaging which will be analyzed using machine learning techniques.
At each study visit of the newly recruited cohorts, appropriate clinical scales will be performed based on their diagnosis and used to track and measure disease severity and progression.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Diagnosis of Parkinson disease
- •Existence of sufficient clinical data from previous UTS Southwestern longitudinal study to determine progression rate (categorized as fast or slow)
- •Availability of suitable matched participant in the alternate progression group (fast or slow)
- •Willingness to participate in the imaging studies required for this study and to provide written informed consent
- •PD subjects will be recruited in accordance with the MDS Clinical Diagnostic Criteria for PD.
- •Duration of PD (since diagnosis) is < 5 years
- •Willing to participate in imaging and clinical scoring visits, and provide written informed consent
- •Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move)
- •MSA subjects will be recruited in accordance with the Second Consensus Statement on Diagnosis of Multiple System Atrophy.
- •Duration of MSA (since diagnosis) is < 5 years
- •Willing to participate in imaging and clinical scoring visits, and provide written informed consent
- •Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move away during the study)
- •PSP subjects will be recruited in accordance with the MDS Criteria for Diagnosis of Progressive Supranuclear Palsy and must meet the designation of "probable PSP" for inclusion.
- •Willing to participate in imaging and clinical scoring visits, and provide written informed consent
- •Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move away during the study)
- •Control subjects will be recruited who meet the following criteria:
- •Roughly age and sex matched with the subjects in the PD cohort
- •No history or examination findings suggestive of any neurodegenerative disease
- •Normal gait, balance, and eye movements for age
- •No clinical evidence for symptomatic orthostatic hypotension
- •Willing to participate in imaging and clinical scoring visits, and provide written informed consent
- •Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move away during the study)
排除标准
- •For Aims 1 and 2:
- •Any contraindications to undergoing the multimodal imaging program
- •All females of child-bearing potential, between the ages of 18-55, will be excluded from the study, unless they are confirmed to be not pregnant with a pregnancy test prior to scanning
- •This study will require constant clear communication throughout the duration of the study; therefore, non-English speakers will be excluded
- •Right-handed finger amputees
- •Cast on right hand or fingers at the time of enrollment
- •Has clinically significant liver, kidney, lung, metabolic or hormone disturbances which pose safety risk
- •Has a current clinically significant heart disease that poses a safety risk
- •Has a current clinically significant infectious disease or a medical comorbidity which poses a safety risk
- •Has a history of relevant severe drug allergy or hypersensitivity
- •Have a history of drug, alcohol, or substance dependence or abuse within the last year, or prior prolonged history of dependence or abuse
- •Currently undergoing chemotherapy or radiation for cancer
- •Recreational drug use in past six months
- •Central nervous systems disease or brain injury that would preclude participation in this study
- •Psychiatric or neurological disorder that would preclude participation in this study
- •Inability to keep or maintain research appointments
- •Severe disease progression such that participation in the imaging tests would be impossible or difficult
- •Non-availability of a suitable matched participant in the alternate progression group (fast or slow)
- •PD subjects
- •Unequivocal cerebellar abnormalities
- •Downward vertical gaze limitation or slowing of downward saccades
- •Diagnosis of behavioral variant frontotemporal dementia or primary progressive aphasia
- •Parkinsonian features restricted to the lower limbs for > 3 years
- •Treatment with dopamine blockers or depleters in a time course consistent with drug induced parkinsonism
- •Absence of an observable response to high dose levodopa despite moderate disease severity
- •Expert considers a diagnosis of alternative syndrome more likely than PD
- •Rapid progression of gait impairment requiring wheelchair within 5 years of onset
- •Complete absence of progression of motor symptoms over 5 years unless due to treatment
- •Early bulbar dysfunction within the first 5 years since diagnosis
- •Inspiratory respiratory dysfunction (stridor or frequent sighs)
- •Severe autonomic failure in the first 5 years
- •Recurrent falls (>1 per year) because of impaired balance in the first 3 years
- •Disproportionate dystonic anterocollis or hand contractures of hands or feet within 10 years
- •Absence of any of the common non-motor features of PD despite 5 years of disease
- •Otherwise unexplained pyramidal tract signs (weakness, hyperreflexia, or extensor toe signs)
- •Bilateral symmetric parkinsonism
- •MSA subjects
- •Clinically significant neuropathy
- •Hallucinations not induced by drugs
- •Onset after age 75 years
- •Family history of ataxia or parkinsonism
- •White matter lesions suggesting multiple sclerosis
- •PSP subjects
- •Predominant, otherwise unexplained impairment of episodic memory, suggestive of AD (Alzheimer's disease)
- •Predominant, otherwise unexplained autonomic failure, e.g., orthostatic hypotension (orthostatic reduction in blood pressure after 3 minutes standing > 30 mm Hg systolic or > 15 mm Hg diastolic), suggestive of multiple system atrophy or Lewy body disease
- •Predominant, otherwise unexplained visual hallucinations or fluctuations in alertness, suggestive of dementia with Lewy bodies
- •Predominant, otherwise unexplained multisegmental upper and lower motor neuron signs, suggestive of motor neuron disease (pure upper motor neuron signs are not an exclusion criterion)
- •Sudden onset or step-wise or rapid progression of symptoms, in conjunction with corresponding imaging or laboratory findings, suggestive of vascular etiology, autoimmune encephalitis, metabolic encephalopathies, or prion disease
- •History of encephalitis
- •Prominent appendicular ataxia
- 另有 3 项未显示
研究组 & 干预措施
Aim 1: Develop a biomarker of PD disease progression rate
For Aim 1, we will enroll PD subjects spanning a range of progression rates that have been tracked at UT Southwestern Medical Center.
Multimodal neuroimaging will be acquired from each subject. We will evaluate imaging data and known data on clinical progression using statistical techniques to determine a biomarker that associates with progression rate.
Aim 2: Develop a biomarker to distinguish between PD, PSP, MSA
For Aim 2, we will recruit subjects with PD, MSA, and PSP. We will also recruit healthy age/sex-matched controls. All subjects will complete a series of clinical assessments at three different time points, roughly 6-8 months apart:
- Levodopa Equivalent Daily Dose
- Parkinson disease questionnaire
- Schwab and England ADL Scale
- MDS-UPDRS (PD and healthy controls only)
- UMSARS (MSA subjects only)
- PSPRS (PSP subjects only)
Multimodal neuroimaging will be acquired from each subject. We will evaluate imaging data from the participants along with prospectively collected information on clinical progression using statistical techniques to determine a biomarker that associates with the differentiation of PD, MSA, and PSP.
结局指标
主要结局
Imaging biomarker that discriminates different neurodegenerative diseases
时间窗: Baseline
The imaging biomarker consists of a machine learning model that differentiates the parkinsonian diseases: PD, PSP, and MSA using the neuroimaging data. The performance of the model will be assessed quantitatively using widely adopted performance metrics from the classification confusion matrix. The metrics will include disease sensitivity, disease specificity, and disease specific accuracy and overall accuracy.
Imaging biomarker of progression rate
时间窗: Baseline
The imaging biomarker consists of a machine learning model that distinguishes fast and slow progressors using the neuroimaging data. The performance of the model will be assessed quantitatively using widely adopted performance metrics: sensitivity, specificity, and accuracy.
次要结局
- Change from baseline in Progressive Supranuclear Palsy Rating Scale (PSPRS) score(Baseline, 6-8 Month Visit, End of Study Visit (12-16 Month))
- Change from baseline in MDS-UPDRS score(Baseline, 6-8 Month Visit, End of Study Visit (12-16 Month))
- Change from baseline in Parkinson disease questionnaire(Baseline, 6-8 Month Visit, End of Study Visit (12-16 Month))
- Change from baseline in Unified Multiple System Atrophy Rating Scale (UMSARS) score(Baseline, 6-8 Month Visit, End of Study Visit (12-16 Month))
- Change from baseline in Schwab and England Activities of Daily Living Scale(Baseline, 6-8 Month Visit, End of Study Visit (12-16 Month))
研究者
Padraig O'Suilleabhain
Professor
University of Texas Southwestern Medical Center